Search Result

Isoforms Recommended:	PPARδ PPARβ/δ

Results for "

PPAR-δ

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PPAR (44) Autophagy (1) COX (3) Endogenous Metabolite (2) Free Fatty Acid Receptor (2) Isotope-Labeled Compounds (2)
By Research Areas:	Cancer (8) Cardiovascular Disease (6) Inflammation/Immunology (7) Metabolic Disease (31) Neurological Disease (5)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: PPAR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107901

Pparδ agonist 1	PPAR	Cardiovascular Disease Metabolic Disease
Pparδ agonist 1 is a *PPAR-δ* agonist, with an EC₅₀ of 5.06 nM, used in the research of PPAR-delta related diseases, such as mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases.

HY-100120

Pparδ agonist 2

PPAR Metabolic Disease

Pparδ agonist 2 is a PPARδ agonist extracted from patent WO 2016057656 A1.

Pparδ agonist 2	PPAR	Metabolic Disease
Pparδ agonist 2 is a *PPARδ* agonist extracted from patent WO 2016057656 A1.

HY-121542

PPARδ agonist 10	PPAR	Metabolic Disease
PPARδ agonist 10 (compound 7) is an orally active, selective, and partial agonist of *PPARδ, with EC₅₀* values of 0.053 μM and 0.30 µM for hPPARδ(LBD)-GAL4 and mPPARδ, respectively. PPARδ agonist 10 is a partial PPARδ agonist in transactivation assay but a full agonist on free fatty acids (FFA) oxidation in muscle cells both in vitro and in vivo. PPARδ agonist 10 can be used for dyslipidemia research .

HY-149429

PPARδ agonist 9	PPAR	Metabolic Disease
PPARδ agonist 9 (compound 21) is a PPARδ agonist (EC₅₀: 3.6 nM). PPARδ agonist 9 has in vivo efficacy, reducing serum levels of MCP-1 in mice and significantly inhibiting atherosclerosis progression in the LDLr-KO model (inhibition rate: 50-60%) .

HY-143862

Pparδ agonist 7	PPAR	Metabolic Disease
Pparδ agonist 7 is a potent agonist of *Pparδ. The peroxisome proliferator-activated receptor (PPAR) is a member of the intranuclear receptor transcription factor superfamily that plays a key role in the regulation of metabolic homeostasis, inflammation, cell growth and differentiation in vivo. Pparδ* agonist 7 has the potential for the research of non-alcoholic fatty liver disease (NAFLD) (extracted from patent WO2019105234A1, compound TM4) .

HY-143863

PPARδ agonist 8	PPAR	Metabolic Disease
Pparδ agonist 8 is a potent agonist of *Pparδ. The peroxisome proliferator-activated receptor (PPAR) is a member of the intranuclear receptor transcription factor superfamily that plays a key role in the regulation of metabolic homeostasis, inflammation, cell growth and differentiation in vivo. Pparδ* agonist 8 has the potential for the research of non-alcoholic fatty liver disease (NAFLD) (extracted from patent WO2021169769A1, compound TM2) .

HY-141494

Pparδ agonist 5	PPAR	Metabolic Disease
Pparδ agonist 5, an orally active PPARδ-selective agonist (EC₅₀=0.335 μM), is much greater than that of the prototypical standard GW0742. Pparδ agonist 5 promotes improvements in bone density and microarchitecture in vivo .

HY-112597

Mavodelpar free acid REN001 free acid; HPP593 free acid; PPARδ agonist	PPAR	Metabolic Disease
Mavodelpar free acid is a *PPARδ* agonist extracted from patent US20180071304, compound example 10. Mavodelpar (free acid) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-120596

PPARδ/γ agonist 1 sodium	PPAR	Neurological Disease
PPARδ/γ agonist 1 sodium is a chemically unique and brain penetrant dual PPAR delta/gamma agonist. PPARδ/γ agonist 1 sodium can be used for the research of Alzheimer’s disease .

HY-124244

DB-959

PPARδ/γ agonist 1
PPAR Neurological Disease

DB-959 (PPARδ/γ agonist 1) is a potent dual PPAR delta/gamma inhibitor. DB-959 can be used for Alzheimer’s disease research .

DB-959 PPARδ/γ agonist 1	PPAR	Neurological Disease
DB-959 (PPARδ/γ agonist 1) is a potent dual PPAR delta/gamma inhibitor. DB-959 can be used for Alzheimer’s disease research .

HY-134377

Bocidelpar ASP0367; MA-0211	PPAR	Metabolic Disease
Bocidelpar is a modulator of peroxisome proliferator-activated receptor delta (PPAR-δ). Bocidelpar improves mitochondrial biogenesis and function in Duchenne Muscular Dystrophy (DMD) muscle cells (extracted from patent WO2017062468A1, compound 2b) .

HY-19522

Seladelpar

MBX-8025

Seladelpar (MBX-8025) is an orally active, potent (50% effect concentration EC₅₀ 2 nM), and specific PPAR-δ agonist .

Seladelpar MBX-8025
Seladelpar (MBX-8025) is an orally active, potent (50% effect concentration EC₅₀ 2 nM), and specific *PPAR-δ* agonist .

HY-20019

L-165041	PPAR	Metabolic Disease
L-165041 is a cell permeable *PPARδ* agonist, with K_is of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively, and induces adipocyte differentiation in NIH-PPARδ cells.

HY-13928

GW0742 10+ Cited Publications GW610742	PPAR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
GW0742 is a potent PPARβ and *PPARδ* agonist, with an IC₅₀ of 1 nM for human *PPARδ* in binding assay, and EC₅₀s of 1 nM, 1.1 μM and 2 μM for human *PPARδ, PPARα, and PPAR*γ, respectively.

HY-17633

Fonadelpar

NPS-005; SJP-0035
PPAR Neurological Disease

Fonadelpar is a PPARδ agonist, used in the research of neuroparalytic keratopathy.
HY-111068

KD-3010

PPAR Metabolic Disease

KD-3010 is a potent, orally active, and selective PPARδ agonist.
HY-10838

GW 501516

10+ Cited Publications

GW 1516; GSK-516
PPAR Autophagy Metabolic Disease Cancer

GW 501516 (GW 1516) is a PPARδ agonist with an EC₅₀ of 1.1 nM .

Fonadelpar NPS-005; SJP-0035	PPAR	Neurological Disease
Fonadelpar is a *PPARδ* agonist, used in the research of neuroparalytic keratopathy.

KD-3010	PPAR	Metabolic Disease
KD-3010 is a potent, orally active, and selective *PPARδ* agonist.

GW 501516 10+ Cited Publications GW 1516; GSK-516	PPAR Autophagy	Metabolic Disease Cancer
GW 501516 (GW 1516) is a *PPARδ* agonist with an EC₅₀ of 1.1 nM .

HY-B0637

Bezafibrate 5 Publications Verification BM15075	PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ*, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-114739

MA-0204	PPAR	Metabolic Disease
MA-0204 is a potent, highly selective and orally available peroxisome proliferator activated receptor δ (PPARδ) modulator with EC₅₀s of 0.4 nM, 7.9 nM and 10 nM for human, mouse and rat PPARδ, respectively. Potential treatment for Duchene Muscular Dystrophy (DMD) .

HY-12377

GSK0660

5 Publications Verification

PPAR Metabolic Disease

GSK0660 is a potent antagonist of PPARβ and PPARδ, with IC₅₀s of 155 nM for both isoforms.

GSK0660 5 Publications Verification	PPAR	Metabolic Disease
GSK0660 is a potent antagonist of PPARβ and *PPARδ, with IC₅₀*s of 155 nM for both isoforms.

HY-B0637S

Bezafibrate-d6	PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate-d₆ is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-B0637S1

Bezafibrate-d4 BM15075-d₄	Isotope-Labeled Compounds PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate-d₄ is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-15577

GSK3787

10+ Cited Publications

PPAR Cancer

GSK3787 is a selective and irreversible peroxisome proliferator-activated receptor δ (PPARδ) antagonist with pIC₅₀ of 6.6.
HY-14817

Indeglitazar

PPM 204
PPAR Metabolic Disease

Indeglitazar (PPM 204) is an orally available PPAR pan-agonist for all three PPARα, PPARδ and PPARγ .

GSK3787 10+ Cited Publications	PPAR	Cancer
GSK3787 is a selective and irreversible peroxisome proliferator-activated receptor δ (PPARδ) antagonist with pIC₅₀ of 6.6.

Indeglitazar PPM 204	PPAR	Metabolic Disease
Indeglitazar (PPM 204) is an orally available *PPAR* pan-agonist for all three PPARα, PPARδ and PPARγ .

HY-147757

PPARγ/δ modulator 1	PPAR	Metabolic Disease
PPARγ/δ modulator 1 (compound 3e) is a potent *PPAR* modulator. PPARγ/δ modulator 1 is a PPARδ antagonist and a PPARγ partial agonist , with K_i values of 14.4 nM and 5.31 μM, respectively. PPARγ/δ modulator 1 has the EC₅₀ of 7.3 and 12.6 μM for PPARδ corepression and adiponectin production, respectively .

HY-120255A

17(S)-HDHA

PPAR Metabolic Disease

17(S)-HDHA is a pro-resolving mediator (SPM). 17(S)-HDHA slightly activats PPARγ, PPARα and PPARδ .

17(S)-HDHA	PPAR	Metabolic Disease
17(S)-HDHA is a pro-resolving mediator (SPM). 17(S)-HDHA slightly activats PPARγ, PPARα and *PPARδ* .

HY-144111

PPARα/δ agonist 1	PPAR	Inflammation/Immunology
PPARα/δ agonist 1 is a potent **PPARα/PPARδ** dual agonist (PPARα EC₅₀=7.0 nM; PPARδ EC₅₀=8.4 nM). PPARα/δ agonist 1 is a high selectivity over PPARγ (PPARγ EC₅₀=1316.1 nM). PPARα/δ agonist 1 has the potential for the research of nonalcoholic steatohepatitis .

HY-16578

GW9662 Maximum Cited Publications 115 Publications Verification	PPAR	Cancer
GW9662 is a potent and selective PPARγ antagonist with an IC₅₀ of 3.3 nM, showing 10 and 1000-fold selectivity over PPARα and PPARδ, respectively.

HY-13861

GW7647 10+ Cited Publications	PPAR	Cardiovascular Disease
GW7647 is a potent PPARα agonist, with EC₅₀s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.

HY-106266

Chiglitazar Carfloglitazar	PPAR	Metabolic Disease
Chiglitazar (Carfloglitazar) is a PPARα/γ dual agonist, with EC₅₀s of 1.2, 0.08, 1.7 μM for PPARα, PPARγ and PPARδ, respectively.

HY-19522A

Seladelpar sodium salt MBX-8025 sodium salt; RWJ-800025 sodium salt	PPAR	Metabolic Disease
Seladelpar sodium salt (MBX-8025) is an orally active, potent and specific *PPARδ* agonist with an EC₅₀ of 2 nM, showing more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively.

HY-106278

GW 590735	PPAR	Metabolic Disease
GW 590735 is a potent and selective PPARα agonist. GW 590735 showsEC₅₀=4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW 590735 can be used for the research of dyslipidemia .

HY-B0760

Fenofibric acid FNF acid	PPAR COX	Metabolic Disease
Fenofibric acid, an active metabolite of fenofibrate, is a *PPAR* activitor, with EC₅₀s of 22.4 µM, 1.47 µM, and 1.06 µM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC₅₀ of 48 nM.

HY-16995

Pirinixic acid 10+ Cited Publications Wy-14643	PPAR	Metabolic Disease Inflammation/Immunology
Pirinixic acid (Wy-14643) is a potent agonist of PPARα, with EC₅₀s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.

HY-112813

TUG-1375 1 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
TUG-1375 is an agonist of free fatty acid receptor 2 (FFA2/GPR43), with a pK_i of 6.69. TUG-1375 is inactive on FFA3, FFA4, PPARα, PPARγ, PPARδ, LXRα or LXRβ .

HY-16578S

GW9662-d5	Isotope-Labeled Compounds PPAR	Cancer
GW9662-d₅ is the deuterium labeled GW9662. GW9662 is a potent and selective PPARγ antagonist with an IC50 of 3.3 nM, showing 10 and 1000-fold selectivity over PPARα and PPARδ, respectively[1][2].

HY-162123

PPARα/δ agonist 2	PPAR	Inflammation/Immunology
PPARα/γ agonist 4 (compound 14) is a potent PPARα and *PPARδ* agonist with EC₅₀s of 3255 nM and 1475 nM for human PPARα and PPARβ/δ, respectively. PPARα/γ agonist 4 shows anti-inflammatory effects .

HY-162320

PPARγ agonist 12	PPAR	Metabolic Disease
PPARγ agonist 12 (compound 9i) is a potent and selective PPARγ agonist with EC₅₀s of 3.98 and 15.42 μM against PPARγ and *PPARδ, respectively. PPAR*γ agonist 12 improves insulin secretion and has anti-diabetic effect .

HY-163443

PPAR agonist 4	PPAR	Others
PPAR agonist 4 (Compound 12) is an orally active agonist for peroxisome proliferator-activated receptor (PPAR), which activates PPARα, PPARδ and PPARγ with EC₅₀s of 0.7, 0.7 and 1.8 μM, respectively. PPAR agonist 4 exhibits anti-liver fibrosis efficacy .

HY-130120

HWL-088	Free Fatty Acid Receptor PPAR	Metabolic Disease
HWL-088 is a highly potent and orally active free fatty acid receptor 1 (FFA1/GPR40) agonist (EC₅₀ of 18.9 nM) with moderate *PPARδ* activity (EC₅₀ of 570.9 nM) . HWL-088 improves glucose and lipid metabolism, and has anti-diabetic effects .

HY-B0760R

Fenofibric acid (Standard) FNF acid (Standard)	PPAR COX	Metabolic Disease
Fenofibric acid (Standard) is the analytical standard of Fenofibric acid. This product is intended for research and analytical applications. Fenofibric acid, an active metabolite of fenofibrate, is a *PPAR* activitor, with EC₅₀s of 22.4 μM, 1.47 μM, and 1.06 μM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC₅₀ of 48 nM.

HY-B0760S

Fenofibric acid-d6	PPAR COX	Metabolic Disease
Fenofibric acid-d₆ (FNF acid-d6) is the deuterium labeled Fenofibric acid. Fenofibric acid, an active metabolite of fenofibrate, is a PPAR activitor, with EC50s of 22.4 µM, 1.47 µM, and 1.06 µM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC50 of 48 nM.

HY-112597A

Mavodelpar REN001; HPP593	PPAR	Inflammation/Immunology
Mavodelpar (REN001) is a selective *PPARδ* agonist. Mavodelpar suppresses glomerular injury and renal fibrosis. Mavodelpar can be used for the research of primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD) . Mavodelpar is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-114263

NXT629 3 Publications Verification	PPAR	Cancer
NXT629 is a potent, selective, and competitive *PPAR-α* antagonist, with an IC₅₀ of 77 nM for human PPARα, shows high selectivity over other nuclear hormone receptor, such as PPARδ, PPARγ, ERβ, GR and TRβ, IC₅₀s are 6.0, 15, 15.2, 32.5 and >100 μM, respectively . NXT629 has potent anti-tumor activity and inhibits experimental metastasis of cancer cell in animal models .

HY-108568

15-Deoxy-Δ-12,14-prostaglandin J2 1 Publications Verification 15d-PGJ2; 15-Deoxy-Δ12,14-PGJ2	PPAR Endogenous Metabolite	Neurological Disease Inflammation/Immunology Cancer
15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC₅₀ of 2 µM) and a covalent *PPARδ* agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC₅₀ of 7 μM .

HY-108568S

15-Deoxy-Δ-12,14-prostaglandin J2-d4 15d-PGJ2-d₄; 15-Deoxy-Δ12,14-PGJ2-d₄	PPAR Endogenous Metabolite	Neurological Disease Inflammation/Immunology Cancer
15-Deoxy-Δ-12,14-prostaglandin J2-d₄ is the deuterium labeled 15-Deoxy-Δ-12,14-prostaglandin J2. 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC50 of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC50 of 7 μM[1][2].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-108568

15-Deoxy-Δ-12,14-prostaglandin J2 1 Publications Verification 15d-PGJ2; 15-Deoxy-Δ12,14-PGJ2	Structural Classification Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	PPAR Endogenous Metabolite
15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC₅₀ of 2 µM) and a covalent *PPARδ* agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC₅₀ of 7 μM .

Cat. No.	Product Name	Chemical Structure

HY-B0637S

Bezafibrate-d6
Bezafibrate-d₆ is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-B0760S

Fenofibric acid-d6
Fenofibric acid-d₆ (FNF acid-d6) is the deuterium labeled Fenofibric acid. Fenofibric acid, an active metabolite of fenofibrate, is a PPAR activitor, with EC50s of 22.4 µM, 1.47 µM, and 1.06 µM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC50 of 48 nM.

HY-108568S

15-Deoxy-Δ-12,14-prostaglandin J2-d4

15-Deoxy-Δ-12,14-prostaglandin J2-d₄ is the deuterium labeled 15-Deoxy-Δ-12,14-prostaglandin J2. 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC50 of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC50 of 7 μM[1][2].

HY-B0637S1

Bezafibrate-d4
Bezafibrate-d₄ is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-16578S

GW9662-d5
GW9662-d₅ is the deuterium labeled GW9662. GW9662 is a potent and selective PPARγ antagonist with an IC50 of 3.3 nM, showing 10 and 1000-fold selectivity over PPARα and PPARδ, respectively[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks